Here's Where Wall Street Analysts See Eli Lilly's Share Price Going
2026-09-26 16:32
•Matthew Benjamin •The Motley Fool
••• •• Axe Cap view
Eli Lilly’s Growth Versus Local Currency Risks
Strong GLP-1 drug sales power Eli Lilly but USD/ZAR dynamics temper enthusiasm.
Eli Lilly’s tirzepatide is driving a new wave of growth in diabetes and weight management, making it one of the most exciting pharma stories globally. Wall Street analysts are cautiously optimistic, with an 11% upside appreciating a $190 billion GLP-1 market by 2045. For South African investors, the key question is how this global success translates into rand terms. The USD/ZAR rate is vulnerable to local political uncertainty and global Fed policy shifts. Even with Lilly’s robust patents and market dominance, currency depreciation could diminish returns for local investors buying through ADRs or ETFs. If the dollar weakens materially against the rand, the story loses luster. Conversely, if the rand maintains its recent resilience, Lilly’s growth story could deliver solid returns. Given these twin engines—innovative drug growth and foreign exchange pressures—patience pays off. this is just our opinion and not financial advice
Watch Eli Lilly as a selective buy on dips, but hedge or trim positions if the rand shows sustained weakness. Remain cautious on currency exposure linked to the USD/ZAR.
- LLY
- USD/ZAR
- Rand depreciation eroding dollar-based gains
- Increased GLP-1 competition from Novo Nordisk
6/10
Eli Lilly's stock has underperformed the broader market in 2026 despite a strong 5-year run, trading at 40x earnings. Wall Street analysts are modestly bullish with an average price target of $1,325 (11% upside), with 25 of 30 analysts recommending buy. The expanding GLP-1 market, projected to reach $190 billion by 2045, and Lilly's strong patent protection through the late 2030s support a positive outlook despite competitive threats from Novo Nordisk.
Our take is based on reporting first published by The Motley Fool.